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Abstract Prostatic urethral lift (PUL) has been shown to
be a safe, effective treatment option for lower urinary
tract symptoms secondary to benign prostatic hyperpla-
sia. Discomfort with PUL is similar to that with rigid
cystoscopy and can be tolerated with local anesthesia in
an office setting. Of those who are given voiding trials,
70–80 % of subjects do not require a catheter. Subjects
often quickly return to pre-operative activity level with
minimal absence from work. Symptom relief can start
within 2 weeks and be sustained through 2 years. Uri-
nary flow rate improvements have been shown to be
durable through 2 years. The most common adverse
effects are dysuria, hematuria, pain, and urgency which
are typically mild to moderate and transient. Sexual
function appears to be preserved after PUL with no
reported new-onset erectile dysfunction or anejaculation
events. The retreatment rate is reported to be 7.5 % at
2 years.
Keywords Benignprostatichyperplasia .Lowerurinary tract
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Introduction
Lower urinary tract symptoms (LUTS) associated with benign
prostatic hyperplasia (BPH) rank number 4 (13.5 %) among
the top 10 diagnosed diseases in men aged 50 years and older,
surpassed only by coronary artery disease/hyperlipidemia, hy-
pertension, and type 2 diabetes mellitus [1]. Chronic LUTS
often lead to loss of sleep, social isolation, and depression,
thus having a significant impact on a patient’s quality of life
[2]. The majority of patients opt for treatment with medica-
tions. Approximately 30 % of men initiating BPH medication
however discontinue treatment early due to insufficient relief
and bothersome side effects [3]. There remains a need for a
BPH treatment that can address LUTS better than medications
yet is associated with less morbidity than current procedures.
Medical therapy with alpha-blockers, 5-alpha-reductase in-
hibitors, or tadalafil, a phosphodiesterase type 5 inhibitor, of-
fers a modest 3- to 6-point improvement in International Pros-
tate Symptom Score (IPSS) and can be associated with both-
ersome side effects, such as sexual dysfunction, dizziness, and
chronic fatigue (asthenia) [4]. Combination therapy can be
more effective in enlarged prostates, but side effects including
erectile dysfunction and decreased libido are additive. As with
many treatment paradigms, the most potent treatments for
LUTS are also associated with the highest risks. Transurethral
resection of the prostate (TURP), first introduced in the 1930s,
is considered the gold standard surgical therapy for BPH [5].
Although highly effective in relieving LUTS, it has a 20 %
rate of perioperative morbidity and long-term complications
that include ejaculatory dysfunction (65 %), erectile dysfunc-
tion (10 %), urinary incontinence (3 %), need for transfusion
(8 %), TUR syndrome (3 %), serious cardiovascular events
(2 %), as well as urethral stricture and bladder neck contrac-
ture (7 %) [4, 6, 7]. New laser-based modalities such as
photoselective vaporization (PVP) may offer less bleeding
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and eliminate TUR syndrome but are otherwise associated
with morbidity rates similar to TURP [8–10]. IPSS im-
provement for TURP or laser procedures ranges 12 to
15 points [4, 9].
Less invasive thermal therapies, namely transurethral mi-
crowave therapy (TUMT) and transurethral needle ablation
(TUNA), offer the ability to treat patients using local or re-
gional anesthesia and reduce the likelihood of the serious
complications seen with tissue removal procedures. Thermal
therapies offer a mean IPSS improvement of 9 to 12 points but
have been associated with urinary retention, routine catheter-
ization, ejaculatory dysfunction, and prolonged irritative
symptoms after the procedure [4, 6, 9].
The prostatic urethral lift (PUL) procedure has been intro-
duced with the goal to better address the needs of a minimally
invasive BPH procedure, namely one that is able to be per-
formed routinely under local anesthesia, with a lower rate of
post-operative catheter usage, more rapid symptom relief with
less morbidity, and preservation of sexual function. Approved
in Europe in 2009, Australia in 2010, and now the USA in
2013, PUL has been studied in several trials. This review
is intended to synthesize the data to examine the risks and
benefits of this new therapy that has entered the urologist’s
BPH treatment armamentarium.
Evidence Analysis
All studies with an estimate of absolute change and either a
95 % confidence interval for the change or a standard devia-
tion were included in the analysis. The estimates were com-
bined across studies using the inverse of the variances for
individual studies for weighting [11]. Per the Fleiss method,
homogeneity was assessed, and where the results were found
to be significantly heterogeneous, the combined estimate of
change was calculated using the heterogeneity adjustment.
P values were calculated to assess the statistical signifi-
cance of the combined estimate of absolute change from
baseline using the calculated combined estimate of change
and standard errors, using the normal distribution.
PUL Surgical Technique
The PUL procedure involves transurethrally placing perma-
nent UroLift® implants (NeoTract, Inc., Pleasanton, CA) un-
der cystoscopic guidance into the prostate gland. The urologist
inserts the handheld delivery device through a sheath and
compresses the prostate lobe with the delivery instrument to
achieve a Bde-obstructed^ effect. Then, the implants are deliv-
ered through a 19-gauge needle that traverses the prostate
gland from the urethra to the capsule. At the end of a suture
housed in the needle, a small metallic tab captures the prostate
capsule and the suture is tensioned. A urethral end piece is
then affixed to the suture, which is then severed. In such a
way, each implant is individually sized in situ to the width of
the compressed lobe at that location. Because the glandular
tissue is more compliant than the fibro-muscular capsule, the
implant lifts the urethra toward the capsule, retracting the
obstructing lateral lobe and enlarging the urethral lumen.
Safety, Effectiveness, and Durability
The PUL procedure was first shown to be safe and feasible by
Woo et al. in a prospective, nonrandomized study of 19 pa-
tients at two Australian centers that started in 2005 [12]. This
study was expanded to more centers and included 64 subjects
who were followed to 2 years [13]. Subjects were at least
55 years old with moderate to severe symptomatic LUTS
(Table 1). Exclusion criteria included obstructive median lobe,
active urinary retention, urinary tract infection, urinary calcu-
lus, or suspicion of prostate cancer. Subjects were evaluated at
0.5, 1, 3, 6, 12, and 24 months after index procedure through
assessments such as the IPSS, quality of life (QoL), BPH
Impact Index (BPH II), peak flow rate (Qmax), post-void
residual volume (PVR), and sexual function scores. Assessed
cystoscopically, PUL was found to visually increase the ure-
thral lumen at the time of treatment. Reported adverse events
were typically mild and transient and included hematuria
(63 %), dysuria (58 %), and irritative symptoms (47 %). There
was significant improvement in symptom scores, with a 14.2-
point improvement in IPSS by 3 months and a 10.7-point
improvement sustained through 1 year. This level of symptom
relief is lower than that typically reported for TURP though
two to three times that of medical therapy [4]. Further, LUTS-
related quality of life, as measured by the QoL and BPH II,
improved significantly (P<0.001 throughout follow-up).
Symptom scores and quality of life measures maintained im-
provement at 2 years, with 9.8-, 2.2-, and 4.1-point improve-
ment in IPSS, QoL, and BPH II, respectively. As a first clinical
study of a new procedure, there was variation in the device
used and the technique employed. The authors explained that
the procedure was significantly refined after the first 25 sub-
jects were treated. This improvement was seen in the rate of
retreatment over 2 years, which was 20% for the entire cohort
but improved to 8 % for the 39 subjects who underwent the
refined procedure.
The largest trial to date of PUL therapy was the random-
ized, controlled, blinded L.I.F.T. study (Luminal Improvement
Following Prostatic Tissue Approximation for the Treatment
of LUTS secondary to BPH) of 206 subjects at 19 centers in
the USA, Canada, and Australia [14•]. Subjects were at least
50 years old, had IPSS score of at least 13, and were random-
ized 2:1 to either PUL procedure or sham control (Table 1). In
North America, the majority of subjects were treated under
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local anesthesia. Subjects returned to preoperative activity lev-
el by 8.6±7.5 days. Adverse events included dysuria (34 %),
hematuria (26 %), pain (26 %), and urgency (7 %). PUL was
found to be significantly more effective at reducing symptoms
than control therapy, with the PUL cohort reporting 88 %
greater reduction in symptoms (P=0.003). Further, PUL ef-
fects were significantly better than control with regard to peak
flow rate, QoL, and BPH II. IPSS was reduced by 11.1 points
(50 %) at 3 months and 10.8 points (49 %) at 1 year. Peak
urinary flow rate increased 4.4 ml/s (64 %) at 3 months and
was sustained to a 4.0-ml/s (59 %) improvement at 12months.
Recently released longer term follow-up of these subjects at
2 years indicates their symptom relief is largely sustained,
with a 9.2-point (42 %) IPSS improvement and a 4.2-ml/s
(58 %) increase in urinary flow rate at 2 years [15••]. Re-
intervention for insufficient response was 5 % at 1 year, rising
to a cumulative 7.5 % by 2 years.
The subjects in the control arm of the L.I.F.T. pivotal trial
were allowed to crossover to active PUL treatment after
unblinding occurred at 3 months. Fifty three of the 66 control
subjects (80 %) met the criteria and elected to crossover
(Table 1). Adverse events included dysuria (36 %), hematuria
(26 %), pain (21 %), urgency (8 %), and urinary retention
(8 %) [17]. The symptom relief achieved by these crossover
procedures was found to be significantly greater than the self-
controlled data from the same subjects after sham procedure and
similar to the original cohort response (11.1- and 8.7-point im-
provement at 3 and 12months, respectively). Quality of life and
BPH II followed the IPSS response, as expected. Urinary flow
rate improved 2.4 ml/s after sham and further improved 2.5 ml/s
at 3 months after PUL. At 12 months, the cumulative improve-
ment in flow rate of 4.6ml/s when compared to pre-index (sham
control) procedure was similar to the randomized study result.
Similarly, the cumulative IPSS improvement when compared to
true baseline before sham control was 10.6, again very similar to
the 10.8 improvement in the randomized study. Investigators
surmised that some residual effect of sham remained at point
of crossover, and the sustained flow rate improvement 3 months
after sham procedure may be a result of a dilatory effect from
rigid cystoscopy. After PUL treatment, one patient (1/53, 2 %)
required re-intervention within the first year.
In addition to highly controlled clinical trials, one publica-
tion describes experience with PUL in standard urologic prac-
tice [19]. An international retrospective study on 102 consec-
utive patients across 7 centers in 5 countries was conducted on
subject data that was collected prospectively (Table 1). No
procedure or results were omitted. Assessment timing and
parameter collection varied at each center but often included
IPSS, QoL, BPH II, Qmax, and PVR through a median
follow-up period of 1 year. Patients received an average of
4.5 implants in prostates of volume 16 through 149 cm3. Ad-
verse events included dysuria (25 %), hematuria (16 %), and
urgency (10 %) with single cases of retention, urinary tract
infection, and orchitis. IPSS improved 12.6 points at 3 months
and 12.3 points at 12 months [19]. Qmax was statistically
elevated at all time points and remained 4.0 ml/s improved
from baseline at 12 months. Seven patients presented in
urinary retention prior to PUL and were catheter free at
the time of reporting (mean 8.3 months). A total of 4 patients
(4/102, 6.5 %) progressed to TURP during the study.
A single-arm prospective study of 51 patients was conducted
at 7 US centers to better elucidate the ability to conduct PUL
under local anesthesia, as well as to quantify the rate of recovery
and improvement in symptoms [18•]. All procedures were suc-
cessfully completed under local anesthetic protocols. Pain visu-
al analog scores indicated that discomfort with PULwas similar
to that of rigid cystoscopy. The authors noted that flexible cys-
toscopy with topical gel lidocaine was a good indicator of tol-
erance of PUL under local anesthesia. Mean catheterization rate
(20 %) and return to pre-operative activity (5.1 days) were
improved from the L.I.F.T. study at these sites. Patients reported
a mean of 2.8 days missed work to undergo PUL, and work
productivity was very high at 1 month post-PUL.
A number of other studies supported the data from these
initial trials [20, 21]. Individual and aggregate data demon-
strate rapid symptomatic improvement that is sustained to at
least 2 years (Fig. 1). Adverse events are mild to moderate and
typically resolve within 2 weeks. Early PUL procedures were
conducted under general anesthesia, but after further develop-
ment, later studies demonstrated the ability to offer PUL as an
outpatient procedure, often using only local anesthesia regi-
mens. Average symptom relief, quality of life, BPH Impact
Index, return to pre-operative activity, peak flow rate improve-
ments, and re-intervention rates were found to be comparable
among published studies (Table 2).
Preservation of Sexual Function
PUL appears not to compromise erectile function as no adverse
event reports of new-onset, sustained erectile dysfunction have
been attributed to the PUL procedure. Further, data from the
feasibility study conducted on 64 patients in Australia indicates
that the erectile function rate as measured by Sexual Health
Inventory for Men (SHIM) score improved after PUL treatment
2.2 points at 3 months and 1.7 points at 12 months (P<0.05)
[22]. Similar results were reported in a pivotal randomized study,
with a 1.3-point improvement at 3 months and a 0.04-point
improvement at 12 months (P<0.05) [16•]. In addition, the
PUL pivotal study demonstrated that those with intact erectile
function at baseline demonstrated stable SHIM scores, which
stands in contrast to the degradation in these subjects reported
after laser vaporization [23, 24]. For PUL, a linear regression of
change vs. baseline condition showed improvement in SHIM as
baseline conditions worsen so that for men entering with severe
erectile dysfunction, SHIM was significantly improved at
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12months (P<0.05). The data from the PUL studies is pointedly
different from the TURP results, where new-onset erectile prob-
lems have been reported in 12 % of patients [25]. This rate has
been shown to be higher than the expected degradation associ-
ated with aging during study follow-up [26].
In addition to potency, ejaculatory function has been found
to significantly influence a patient’s sex life [27]. In a recent
review, Sturch et al. purport that many men would accept a
reduction in treatment efficacy to preserve ejaculation [28].
An aspect of ejaculation that is often compromised by sur-
gical BPH treatment is the emission of ejaculate during
sexual activity. Unlike TURP, treatment with the PUL sys-
tem showed no compromise in regard to the ability to emit
ejaculate. There have been no adverse event reports of
new-onset, sustained dry emission (anejaculation or retro-
grade ejaculation) attributed to the PUL procedure. Further,
in the feasibility study, ejaculatory function as measured by
the Male Sexual Health Questionnaire for Ejaculatory Dys-
function (MSHQ-EjD) function score increased slightly at
all time points and was statistically significant at 6 weeks
(1.7 points) and 3 months (1.6 points) [22]. In the larger
pivotal study, ejaculatory function was similarly statistically
improved at each time point during follow-up, with a 2.2-
point increase at 3 months and a 1.3-point increase at
12 months. Individual MSHQ-EjD element analysis also
revealed that frequency, strength, and volume of semen
were also statistically improved at each time point [16•].
Conclusion
The prostatic urethral lift is a new option for the treatment of
LUTS secondary to BPH. It offers rapid relief of LUTS with a
lower risk of morbidity than standard interventional options.
Multiple studies have demonstrated symptom relief that may
initiate within 2 weeks and be potentially sustained through
2 years. LUTS-related quality of life, as measured by the IPSS
quality of life question and the BPH Impact Index, also im-
proves after PUL. Randomized and open-label studies have
demonstrated that PUL can be delivered using local anesthesia
(intraurethral and oral medications) with acceptable patient
comfort. Post-operative catheterization, when tested via void
trial, has been shown to be 20 to 30 % with an average dura-
tion of less than 1 day.
Durability of the PUL system treatment has been demon-
strated to 2 years with a mean IPSS improvement of 47–49 %
at 1 year and 42–45 % at 2 years, indicating a stable response
[13, 15••]. Re-intervention rates for disease progression have
to date remained low, occurring in approximately 7.5 % of
patients at 2 years [15••].
Sexual function appears to be preserved after PUL with no
reported incidence of new-onset, sustained erectile dysfunc-
tion or dry emission with ejaculation. PUL may even improve
sexual performance in patients, as average SHIM and MSHQ-
EjD function scores increased after treatment inmultiple studies.
Ejaculatory function can be compromised after pharmacologic
and interventional LUTS treatments, an issue which has re-
ceived overdue attention and represents an important quality
of life aspect for patients. Because no tissue is destroyed or
removed with PUL and ejaculatory function is preserved, it
may be uniquely positioned to address BPH LUTSwhile simul-
taneously preserving sexual function.
Although recently approved in the USA for BPH LUTS
treatment, this therapy (PUL) has been under investigation
since 2005 and has been reported in numerous clinical studies.
The breadth, depth, and repeatability of PUL data through
Fig. 1 Aggregate IPSS response
after treatment with PUL from six
cohort studies shows rapid and
durable symptom relief through
2 years. Dotted lines represent
95 % confidence intervals.
IPSS International Prostate
Symptom Score
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multiple international trials with varying investigator experi-
ence, patient populations, and health care systems indicate that
the outcomes after PUL are not setting dependent and support
the technology in the treatment of real-world patient settings.
Because PUL is well tolerated and associated with few
risks in comparison to most interventional LUTS alternatives,
it may appeal to men who are earlier in their BPH disease
progression. Moreover, instead of remaining on palliative
medications that may have bothersome side effects, these
men may elect a minimal risk solution that is potentially more
effective and durable and has the potential to preserve their
sexual function. The ability to beneficially affect a population
of younger men who traditionally would have received no
therapy or marginally tolerated pharmacological therapy
may represent a paradigm shift for interventional BPH therapy
with the advent of PUL.
Table 2 Effectiveness of PUL as demonstrated through International Prostate Symptom Score (IPSS), quality of life (QoL), BPH Impact Index
(BPH II), and peak flow rate (Qmax) change from baseline through 2 years from published studies
2 weeks 1–1.5 months 3 months 6 months 1 year 2 years
IPSS
# studies 3 [14•, 15••, 17, 18•] 3 [14•, 15••, 17, 18•] 2 [14•, 15••, 17] 2 [14•, 15••, 17] 2 [14•, 15••, 17] 1 [14•, 15••]
Total patients 244 244 193 193 193 140
Change from
baseline
−4.5 −10.2 −11.1 −10.8 −9.8 −9.2
95 % CI −5.5, −3.5 −11.1, −9.4 −12.2, −10.1 −11.9, −9.7 −11.7, −8.0 −10.7, −7.8
P value <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
% improvement −18 −45 −49 −47 −45 −42
QoL
# studies 3 [14•, 15••, 17, 18•] 3 [14•, 15••, 17, 18•] 2 [14•, 15••, 17] 2 [14•, 15••, 17] 2 [14•, 15••, 17] 1 [14•, 15••]
Total patients 244 244 193 193 193 140
Change from
baseline
−1.2 −2.1 −2.2 −2.3 −2.2 −2.2
95 % CI −1.5, −0.80 −2.3, −1.8 −2.5, −2.0 −2.6, −2.1 −2.5, −2.0 −2.6, −1.9
P value <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
% improvement −22 −43 −47 −49 −49 −48
BPH II
# studies 3 [14•, 15••, 17, 18•] 3 [14•, 15••, 17, 18•] 2 [14•, 15••, 17] 2 [14•, 15••, 17] 2 [14•, 15••, 17] 1 [14•, 15••]
Total patients 244 244 193 193 193 140
Change from
baseline
−0.1 −3.0 −3.8 −4.0 −3.6 −3.8
95 % CI −0.7, 0.5 −3.4, −2.6 −4.2, −3.3 −4.4, −3.5 −4.4, −2.7 −4.4, −3.1
P value 0.85 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
% improvement 21 −38 −55 −58 −55 −56
Qmax
# studies 1 [18•] 2 [14•, 15••, 17] 2 [14•, 15••, 17] 1 [14•, 15••]
Total patients 51 193 193 140
Change from
baseline
3.3 3.8 3.3 4.15
95 % CI 2.1, 4.5 3.1, 4.5 1.9, 4.8 3.1, 5.2
P value <0.0001 <0.0001 <0.0001 <0.0001
% improvement 47 50 49 58
PVR
# studies 2 [12, 13, 19] 2 [12, 13, 19] 4 [12, 13, 14•, 15••,
17, 19]
2 [12, 13, 19] 4 [12, 13, 14•, 15••,
17, 19]
1 [12, 13]
Total patients 166 166 359 166 359 64
% change from
baseline
−5.7 7.7 −9.4 −19.4 0.9 63
95 % CI −25.1, 13.7 −16.0, 31.2 −25.2, 6.4 −37.5, −1.3 −16.9, 18.7 −3, 130
P value 0.56 0.53 0.24 0.036 0.92 0.061
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